Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 266 | 57 | 196 |
| Samples | 229 | 48 | 173 |
| Peptides | 186 | 33 | 157 |
Function
NUB1 · Negative regulator of ubiquitin like proteins 1
This gene encodes a protein that functions as a negative regulator of NEDD8, a ubiquitin-like protein that conjugates with cullin family members in order to regulate vital biological events. The protein encoded by this gene regulates the NEDD8 conjugation system post-transcriptionally by recruiting NEDD8 and its conjugates to the proteasome for degradation. This protein interacts with the product of the AIPL1 gene, which is associated with Leber congenital amaurosis, an inherited retinopathy, and mutations in that gene can abolish interaction with this protein, which may contribute to the pathogenesis. This protein is also known to accumulate in Lewy bodies in Parkinson's disease and dementia with Lewy bodies, and in glial cytoplasmic inclusions in multiple system atrophy, with this abnormal accumulation being specific to alpha-synucleinopathy lesions. Alternative splicing of this gene results in multiple transcript variants. [provided by RefSeq, Aug 2011].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 171 amino-acid changes on canonical ENST00000470229 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NUB1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NUB1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 7/612 1% |
| Melanoma | 3/210 1% | 29/1899 2% |
| Gastric Carcinoma | 2/74 3% | 19/1809 1% |
| Bladder Carcinoma | 0/58 0% | 11/956 1% |
| Colorectal Carcinoma | 9/143 6% | 25/3239 1% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Burkitts Lymphoma | 0/32 0% | 2/196 1% |
| Other Solid Cancers | 3/94 3% | 11/1515 1% |
| Head and Neck Carcinoma | 1/85 1% | 11/1574 1% |
| Biliary Tract Carcinoma | 0/54 0% | 6/950 1% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 4/1390 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Breast Carcinoma | 3/144 2% | 8/3264 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 5/1592 0% |
| Hepatocellular Carcinoma | 0/46 0% | 6/2210 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Pancreatic Carcinoma | 0/89 0% | 4/1611 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Kidney Carcinoma | 1/85 1% | 3/1862 0% |
| Neuroblastoma | 3/87 3% | 0/1331 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 3/2534 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Glioma | 0/52 0% | 4/2127 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
Mutation Distribution
Where NUB1 is mutated · all tissues, split by cell line vs tissue
How many mutations in NUB1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 266 mutations in NUB1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|